Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial.
Sheung-Yin FanHoi-Ping ShumWing-Yee ChengYat-Hei ChanSik-Yin McShirley LeungWing Wa YanPublished in: Pharmacotherapy (2017)
Both the EI and NEI groups demonstrated similar 14-day mortality. Post hoc subgroup analysis revealed a mortality benefit in patients in the EI group who had infectious organisms identified or were diagnosed with respiratory tract infections.
Keyphrases
- respiratory tract
- clinical trial
- end stage renal disease
- cardiovascular events
- ejection fraction
- chronic kidney disease
- risk factors
- prognostic factors
- low dose
- peritoneal dialysis
- randomized controlled trial
- cardiovascular disease
- patient reported outcomes
- single cell
- high intensity
- coronary artery disease
- phase iii
- phase ii
- multidrug resistant
- double blind